97% 准确率的血液检测可检测出早期胰腺癌；Oncolytics Biotech Inc. 推进免疫疗法 pelareorep 用于治疗。 97%-accurate blood test detects early-stage pancreatic cancer; Oncolytics Biotech Inc. advances immunotherapy pelareorep for treatment.

一项突破性的血液检测在检测早期胰腺癌方面具有 97% 的准确率，为对抗这种最致命的癌症之一带来了希望。 A groundbreaking blood test with a 97% accuracy rate in detecting early-stage pancreatic cancer brings hope to the fight against one of the deadliest cancers. Oncolytics Biotech Inc. 等生物技术公司正在致力于推进新的治疗方法，其免疫治疗药物 pelareorep 显示出治疗乳腺癌和胰腺癌的良好前景。 Biotech companies, such as Oncolytics Biotech Inc., are working on advancing new treatments, with their immunotherapeutic agent, pelareorep, showing promise for breast and pancreatic cancer treatment. Oncolytics 已获得 FDA 颁发的胰腺癌快速通道资格，并正在与全球适应性研究联盟合作评估 pelareorep。 Oncolytics has received Fast Track Designation from the FDA for pancreatic cancer and is collaborating with the Global Coalition for Adaptive Research in evaluating pelareorep.